









市场行情
/
股票
/
nasdaq-rgnx
/

Regenxbio Inc

RGNX

14.160USD

-0.300-2.07%

收盘 12/26, 16:00（美东）报价延迟15分钟

716.77M总市值

亏损市盈率 TTM



Regenxbio Inc

14.160

-0.300-2.07%

概览公司财务分析

概览

公司

财务

分析

关于 Regenxbio Inc 公司

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Regenxbio Inc简介



公司代码RGNX

公司名称Regenxbio Inc

上市日期Sep 17, 2015

CEOSimpson (Curran M)

员工数量353

证券类型Ordinary Share

年结日Sep 17

公司地址9804 Medical Center Drive

城市ROCKVILLE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编20850

电话12405528181

网址https://regenxbio.com/

公司代码RGNX

上市日期Sep 17, 2015

CEOSimpson (Curran M)

Regenxbio Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-55.17%

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

53.97K

-8.33%

Ms. Jennifer L. Zachary

Independent Director

20.06K

+63.21%

Mr. Daniel Tasse

Lead Independent Director

19.05K

+68.83%

Mr. George V. Migausky

Independent Director

19.05K

+68.83%

Mr. Craig Malzahn

Executive Vice President - Product Development, Chief Technology Officer

17.59K

-1.31%

Mr. Curran M. Simpson

President, Chief Executive Officer, Director

16.11K

-48.81%

Mr. Allan M. Fox, J.D.

Director

Dr. David C. (Dave) Stump, M.D.

Independent Director

Dr. A. N. (Jerry) Karabelas, Ph.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-55.17%

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

53.97K

-8.33%

Ms. Jennifer L. Zachary

Independent Director

20.06K

+63.21%

Mr. Daniel Tasse

Lead Independent Director

19.05K

+68.83%

Mr. George V. Migausky

Independent Director

19.05K

+68.83%

Mr. Craig Malzahn

Executive Vice President - Product Development, Chief Technology Officer

17.59K

-1.31%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Redmile Group, LLC

9.27%

BlackRock Institutional Trust Company, N.A.

8.21%

The Vanguard Group, Inc.

6.59%

Fox (Allan Mark)

5.73%

JP Morgan Asset Management

5.16%

其他

65.04%

持股股东

占比

Redmile Group, LLC

9.27%

BlackRock Institutional Trust Company, N.A.

8.21%

The Vanguard Group, Inc.

6.59%

Fox (Allan Mark)

5.73%

JP Morgan Asset Management

5.16%

其他

65.04%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

33.68%

Investment Advisor

31.08%

Research Firm

9.14%

Hedge Fund

8.88%

Individual Investor

7.60%

Private Equity

0.50%

Family Office

0.31%

Bank and Trust

0.25%

Pension Fund

0.11%

其他

8.44%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

403

44.05M

87.32%

-5.71M

2025Q2

421

48.19M

95.62%

-3.63M

2025Q1

446

48.46M

96.35%

-3.90M

2024Q4

444

48.16M

97.22%

-4.82M

2024Q3

444

49.64M

100.43%

-4.45M

2024Q2

437

49.30M

99.98%

-3.20M

2024Q1

451

48.23M

99.21%

+414.63K

2023Q4

436

43.62M

98.84%

-7.14M

2023Q3

439

43.73M

99.56%

-6.26M

2023Q2

439

43.86M

100.57%

-5.31M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Redmile Group, LLC

4.78M

9.45%

-19.06K

-0.40%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.27M

8.45%

+348.80K

+8.90%

Jun 30, 2025

The Vanguard Group, Inc.

3.42M

6.77%

-51.80K

-1.49%

Jun 30, 2025

Fox (Allan Mark)

2.90M

5.74%

+7.77K

+0.27%

May 30, 2025

JP Morgan Asset Management

2.99M

5.91%

+38.82K

+1.32%

Jun 30, 2025

State Street Investment Management (US)

1.84M

3.65%

+777.55K

+72.93%

Jun 30, 2025

Goldman Sachs & Company, Inc.

1.61M

3.18%

+962.62K

+149.64%

Jun 30, 2025

BlackRock Financial Management, Inc.

1.73M

3.43%

+637.97K

+58.36%

Jun 30, 2025

Morgan Stanley & Co. LLC

744.88K

1.47%

-822.49K

-52.48%

Jun 30, 2025

AQR Capital Management, LLC

930.20K

1.84%

+309.60K

+49.89%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

WisdomTree BioRevolution Fund

2.25%

iShares Neuroscience and Healthcare ETF

1.02%

Virtus LifeSci Biotech Clinical Trials ETF

0.85%

Global X Genomics & Biotechnology ETF

0.65%

JPMorgan Fundamental Data Science Small Core ETF

0.45%

ALPS Medical Breakthroughs ETF

0.27%

State Street SPDR S&P Biotech ETF

0.24%

Direxion Daily S&P Biotech Bull 3X Shares

0.13%

Fidelity Enhanced Small Cap ETF

0.12%

ProShares Ultra Nasdaq Biotechnology

0.08%

WisdomTree BioRevolution Fund

占比2.25%

iShares Neuroscience and Healthcare ETF

占比1.02%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.85%

Global X Genomics & Biotechnology ETF

占比0.65%

JPMorgan Fundamental Data Science Small Core ETF

占比0.45%

ALPS Medical Breakthroughs ETF

占比0.27%

State Street SPDR S&P Biotech ETF

占比0.24%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.13%

Fidelity Enhanced Small Cap ETF

占比0.12%

ProShares Ultra Nasdaq Biotechnology

占比0.08%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Regenxbio Inc的前五大股东是谁？



Regenxbio Inc 的前五大股东如下：
Redmile Group, LLC持有股份：4.78M，占总股份比例：9.45%。
BlackRock Institutional Trust Company, N.A.持有股份：4.27M，占总股份比例：8.45%。
The Vanguard Group, Inc.持有股份：3.42M，占总股份比例：6.77%。
Fox (Allan Mark)持有股份：2.90M，占总股份比例：5.74%。
JP Morgan Asset Management持有股份：2.99M，占总股份比例：5.91%。